Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 3/20 | 0.56 |
| ▸ | PRKCG | P05129 | 3/20 | 0.56 |
| ▸ | PRKCB | P05771 | 3/20 | 0.56 |
| ▸ | PRKCA | P17252 | 3/20 | 0.56 |
| ▸ | PRKCH | P24723 | 3/20 | 0.56 |
| ▸ | PRKCI | P41743 | 3/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10344073 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8674072 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL7718400 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL1772881 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Bromide SCHEMBL31481144 | 0.98 | PRKD3 (0.58) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL7720158 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL7720123 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL1773674 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL9808821 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL1773357 | 0.98 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3415151-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University of British Columbia (CA) | 2018-12-19 | — | — | EP | claimed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | claimed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | claimed |
| US-8545876-B1 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | claimed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | claimed |
| EP-0187702-B1 | N-(OMEGA,OMEGA-1-DIALKOXY)- AND N-(OMEGA,OMEGA-1-DIALKENOXY)-ALK-1-YL-N,N,N-TRISUBSTITUTED AMMONIUM SURFACTANTS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1990-03-14 | — | — | EP | claimed |
| WO-2026102108-A1 | DNA PRODUCTION METHODS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125728-A1 | DNA PRODUCTION METHODS | FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260098014-A1 | IONIZABLE LIPIDOID COMPOSITIONS AND THERAPEUTIC USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4711465-A2 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS | Fred Hutchinson Cancer Center (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12576131-B2 | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4166161-B1 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-04 | — | — | EP | disclosed |
| US-8545876-B1 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576131-B2 | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | TP53, IRF3, IGFBP5 | PRKD3 868/4885PRKCG 808/4885PRKCB 584/4885 |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PRKD3 4142/4885PRKCG 3913/4885PRKCB 4318/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | PRKD3 3804/4885PRKCG 4293/4885PRKCB 4584/4885 |
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SGMS1, NPC1L1, SGMS2 | PRKD3 781/4885PRKCG 646/4885PRKCB 486/4885 |
| US-20260098014-A1 | IONIZABLE LIPIDOID COMPOSITIONS AND THERAPEUTIC USES THEREOF | NPC1L1, LDLR, NPC1 | PRKD3 812/4885PRKCG 954/4885PRKCB 762/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PRKD3 4142/4885PRKCG 3913/4885PRKCB 4318/4885 |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PRKD3 4142/4885PRKCG 3913/4885PRKCB 4318/4885 |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PRKD3 4142/4885PRKCG 3913/4885PRKCB 4318/4885 |
| US-20260125728-A1 | DNA PRODUCTION METHODS | DNA2, DNMT3A, DNMT3L | PRKD3 3525/4885PRKCG 3408/4885PRKCB 2601/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | PRKD3 3804/4885PRKCG 4293/4885PRKCB 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.